Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

CEO Heather Bresch gave a soliloquy on US health care during the second quarter call, saying ‘perverse incentives’ have created a system that ‘feeds on higher prices.’

Cropped image of man holding the world map in hands while standing near private plane in airport. Choosing the next destination.

Mylan NV's board of directors announced Aug. 8 that it is reviewing strategic alternatives for the company as the generic drug manufacturer's stock price has remained undervalued, and as the company said US pharmaceutical trends are unsustainable. The news coincided with disappointing second quarter financial results, with Mylan's North American sales down 22% under intense pressure.

The lower sales were largely due to a manufacturing setback at the company's plant in Morgantown, W.Va. manufacturing facility following...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.